Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida.

Hampp C, Saidi AS, Winterstein AG.

J Pediatr. 2010 Jun;156(6):953-9, 959.e1. doi: 10.1016/j.jpeds.2009.12.016. Epub 2010 Mar 10.

PMID:
20223478
[PubMed - indexed for MEDLINE]
2.

A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.

Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.

J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. Review.

PMID:
20131495
[PubMed - indexed for MEDLINE]
Free Article
3.

Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.

Diehl JL, Daw JR, Coley KC, Rayburg R.

J Manag Care Pharm. 2010 Jan-Feb;16(1):23-31.

PMID:
20044844
[PubMed - indexed for MEDLINE]
Free Article
4.

Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.

Lundeen K, Pfeiffenberger T, Jacobson Vann J, O'Brien T, Sampson C, Wegner S.

J Manag Care Pharm. 2013 Mar;19(2):115-24.

PMID:
23461427
[PubMed - indexed for MEDLINE]
Free Article
5.

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.

Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.

Pediatr Pulmonol. 2008 Feb;43(2):169-74.

PMID:
18085710
[PubMed - indexed for MEDLINE]
6.

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.

Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group.

J Perinatol. 2008 Jul;28(7):511-7. doi: 10.1038/jp.2008.28. Epub 2008 Mar 27.

PMID:
18368063
[PubMed - indexed for MEDLINE]
7.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
[PubMed - indexed for MEDLINE]
8.

Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.

Hampp C, Kauf TL, Saidi AS, Winterstein AG.

Arch Pediatr Adolesc Med. 2011 Jun;165(6):498-505. doi: 10.1001/archpediatrics.2010.298. Epub 2011 Feb 7.

PMID:
21300647
[PubMed - indexed for MEDLINE]
10.

Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.

Lacaze-Masmonteil T, Rozé JC, Fauroux B; French Pediatricians' Group of Sunagis Patients' Name-Based Programs.

Pediatr Pulmonol. 2002 Sep;34(3):181-8.

PMID:
12203846
[PubMed - indexed for MEDLINE]
11.

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.

Sorrentino M, Powers T.

Pediatr Infect Dis J. 2000 Nov;19(11):1068-71.

PMID:
11099087
[PubMed - indexed for MEDLINE]
12.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376
[PubMed - indexed for MEDLINE]
13.

Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.

Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O.

Arch Dis Child Fetal Neonatal Ed. 2005 Jan;90(1):F64-8.

PMID:
15613580
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.

Curtiss FR, Fairman KA.

J Manag Care Pharm. 2010 Jan-Feb;16(1):59-66. No abstract available.

PMID:
20044846
[PubMed - indexed for MEDLINE]
Free Article
15.

Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.

Groothuis JR.

Eur J Clin Microbiol Infect Dis. 2003 Jul;22(7):414-7. Epub 2003 Jun 24.

PMID:
12827537
[PubMed - indexed for MEDLINE]
16.

Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.

Warren A, Langley JM, Thomas W, Scott J.

Can J Cardiol. 2007 May 1;23(6):463-6. Erratum in: Can J Cardiol. 2010 Jan;15(1):22.

PMID:
17487291
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.

Pediatrics. 2003 Dec;112(6 Pt 1):1442-6.

PMID:
14654627
[PubMed - indexed for MEDLINE]
19.

Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry.

Cohen SA, Zanni R, Cohen A, Harrington M, VanVeldhuisen P, Boron ML; Palivizumab Outcomes Registry Group.

Pediatr Cardiol. 2008 Mar;29(2):382-7. Epub 2007 Oct 10.

PMID:
17926087
[PubMed - indexed for MEDLINE]
20.

Prevention of respiratory syncytial virus infection with palivizumab.

Thomas M, Bedford-Russell A, Sharland M.

Monaldi Arch Chest Dis. 2000 Aug;55(4):333-8. Review.

PMID:
11057088
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk